FSD Pharma Announces Agreement To Grant Exclusive Rights To Recreational Alcohol Misuse Technology
Portfolio Pulse from Lara Goldstein
FSD Pharma (NASDAQ:HUGE) has signed a Letter of Intent with 1319741 B.C. Ltd., soon to be renamed Celly Nutrition Inc., to grant exclusive rights to recreational applications for FSD Pharma's alcohol misuse technology. The new company will have Coca-Cola (NYSE:KO) veteran John Duffy as CEO and former Celsius CEO Gerry David and marketing expert Kevin Harrington as Advisory Board members.
June 20, 2023 | 8:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FSD Pharma signs LOI with Celly Nutrition to grant exclusive rights to recreational applications for alcohol misuse technology, potentially increasing revenue and shareholder value.
FSD Pharma's agreement with Celly Nutrition to grant exclusive rights to their alcohol misuse technology for recreational applications could lead to increased revenue and shareholder value. The new company will be led by experienced executives, which may positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Coca-Cola veteran John Duffy will be the CEO of the new company formed by FSD Pharma and Celly Nutrition, but the impact on Coca-Cola's stock is minimal.
Although Coca-Cola veteran John Duffy will be the CEO of the new company formed by FSD Pharma and Celly Nutrition, this news is not directly related to Coca-Cola's operations or financial performance. Therefore, the impact on Coca-Cola's stock price is expected to be minimal.
CONFIDENCE 90
IMPORTANCE 10
RELEVANCE 20